Team 10
Hydrogel Dressing for Targeted Antibiotic Delivery in Treatment of Skin and Soft Tissue Infections
Hydrogel Dressing for Targeted Antibiotic Delivery in Treatment of Skin and Soft Tissue Infections
Team Members: Fernando Aguilera de Alba, Raneem Asiri, David Asuncion, Beerjas Bath & Kasandra Sanchez
Team Mentors: Brent Vernon, Ph.D - SBHSE
Eric Nguyen - Creighton University School of Medicine
YouTube Link: View the video link below before joining the zoom meeting
Zoom Link: https://asu.zoom.us/j/86393286063
Abstract
Skin and soft tissue infections (SSTIs) have been reported as the third most common diagnosis in emergency care settings. They account for 2% of all hospital admissions, and on average, a patient will spend approximately $22,706 to receive intravenous antibiotics when hospitalized. The majority of SSTIs are attributed to gram-positive bacteria such as Staphylococcus Aureus and group A Streptococcus. Depending on the severity, infections are treated with either topical, oral, or intravenous antibiotics, such as cephalexin, doxycycline, or cefazolin. The combination of these strong antibiotics and systemic absorption is associated with a number of negative side effects, including the elimination of pathogenic and non-pathogenic bacteria. A hydrogel dressing, HydroBiotix, is aimed to target infections locally through continuous release of antibiotics to eradicate infection while conserving non-pathogenic bacteria. The dressing will significantly reduce adverse effects, hospital admissions, and treatment costs. Continuous local antibiotics will provide an equally effective treatment while drastically reducing the side effects experienced with existing treatments. The concept for HydroBiotix was developed by evaluating customer data, establishing customer needs, and translating these needs into target product specifications. HydroBiotix will enhance antibiotic drug delivery by providing a sustained, long-term, and localized release of the drug in order to prevent side effects of oral antibiotic intervention. Future directions for HydroBiotix will include physical prototype development and validation of the design.
